SCHEMBL3319048

SCHEMBL3319048

O=[N+]([O-])c1ccccc1S(=O)(=O)N(Cc1ccc(CNC2CCc3cccc(O)c3C2)cc1)Cc1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 8/20 0.39
PTPN1 P18031 2/20 0.39
KCNA5 P22460 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
GRIN2B Q13224 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2C P18825 1/20 0.35
NPY1R P25929 1/20 0.35
NPY5R Q15761 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308503 0.92 KCNA5 (0.42) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL3311009 0.88 KCNA5 (0.40) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL3312846 0.79 HDAC6 (0.48) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL3314317 0.79 HDAC6 (0.46) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL3308573 0.76 KCNA5 (0.51) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL4069825 0.76 CXCR3 (0.41) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL3314915 0.76 HDAC6 (0.42) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL4069997 0.75 PDE4A (0.42) CXCR3PTPN1KCNA5HDAC3HDAC11
SCHEMBL29823341 0.75 GRIN2B (0.45) GRIN2BDRD2
SCHEMBL1876490 0.75 GRIN2B (0.45) GRIN2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2010-04-29 US disclosed
US-7629337-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2009-12-08 US disclosed
US-7183273-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2007-02-27 US disclosed
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds ANORMED INC. (CA) 2006-11-23 US disclosed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 EP disclosed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 US disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 CXCR3 4/4885PTPN1 1148/4885KCNA5 1834/4885
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CXCR4, CCR5, CXCR3 CXCR3 3/4885PTPN1 2908/4885KCNA5 4429/4885
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 CXCR3 6/4885PTPN1 1129/4885KCNA5 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.